Live from the NIH registry
Studies recruiting near Springfield right now
Top 25 of 152 recruiting studies, sorted by proximity — each links to its official registry page
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
Phase 3
Interventional 768 participants sought
Hulston Cancer Center /ID# 232226 — Springfield, Missouri (1.5 mi)
· Sponsor: AbbVie
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Hidradenitis Suppurativa
Phase 1
Interventional 24 participants sought
Red River Research Partners — Bolivar, Missouri (29.8 mi)
· Sponsor: Incyte Corporation
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma
Phase 2
Interventional 87 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Phase 3
Interventional 364 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: SWOG Cancer Research Network
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Phase 2
Interventional 146 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
CoxHealth South Hospital — Springfield, Missouri (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Renal Pelvis and Ureter Urothelial Carcinoma
Phase 2, Phase 3
Interventional 131 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Phase 3
Interventional 10,000 participants sought
Mercy Research — Springfield, Missouri (1.5 mi)
· Sponsor: Novo Nordisk A/S
Pan-tumor MRD Study
Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer
N/A
Observational 1,350 participants sought
Cox Health — Springfield, Missouri (1.5 mi)
· Sponsor: Paradigm Health
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma
Phase 3
Interventional 1,210 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Atopic Dermatitis
N/A
Observational 1,000 participants sought
Red River Research Partners, Llc- Site Number : 8400054 — Bolivar, Missouri (29.8 mi)
· Sponsor: Sanofi
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
N/A
Observational 2,062 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: SWOG Cancer Research Network
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma
Phase 3
Interventional 336 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
Alzheimer's Disease
Phase 2
Interventional 407 participants sought
Citizens Memorial Hospital Neurology CLinic — Bolivar, Missouri (29.8 mi)
· Sponsor: Novartis Pharmaceuticals
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Fibromyalgia
Phase 3
Interventional 620 participants sought
Clinical Research Site — Springfield, Missouri (1.5 mi)
· Sponsor: Axsome Therapeutics, Inc.
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2, Phase 3
Interventional 613 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Phase 2
Interventional 240 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: NRG Oncology
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Phase 2, Phase 3
Interventional 992 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
Phase 3
Interventional 303 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
N/A
Observational 20,000 participants sought
CoxHealth — Springfield, Missouri (1.5 mi)
· Sponsor: Heart Rhythm Clinical and Research Solutions, LLC
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
N/A
Observational 800 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: University of Rochester
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Cognitive Dysfunction, Lewy Body Disease
Phase 2
Interventional 350 participants sought
Citizens Memorial Hospital District — Bolivar, Missouri (29.8 mi)
· Sponsor: Eli Lilly and Company
Galleri® in the Medicare Population.
Cancer
N/A
Interventional 50,000 participants sought
Mercy Health - Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: GRAIL, Inc.
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Phase 3
Interventional 600 participants sought
Cox Medical Center North ( Site 0133) — Springfield, Missouri (1.5 mi)
· Sponsor: Merck Sharp & Dohme LLC
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3
Interventional 1,100 participants sought
Mercy Hospital Springfield — Springfield, Missouri (1.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology